Drug Trial Radar · NCT00223691
Treatment of Orthostatic Hypotension in Autonomic Failure
Last checked: Nov 19, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
389
Actual
Start
Mar 2002
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- Vanderbilt UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
Conditions
- Autonomic Failure
- Orthostatic Hypotension
Interventions
AtomoxetineDrug
10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
AcarboseDrug
25-100 mg, PO. Single dose.
Pyridostigmine BromideDrug
30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
YohimbineDrug
2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
Midodrine HClDrug
2.5, 5.0, 7.5, 10 mg PO. Single dose
placeboDrug
PO.Single dose.
ModafinilDrug
50-400 mg PO. Single dose
OctreotideDrug
5-50 µg, S.C. Single dose.
water intakeOther
Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
Diphenhydramine HydrochlorideDrug
12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
Ranitidine HCLDrug
150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
TranylcypromineDrug
5 - 40 mg PO. Single dose
Ergotamine/ CaffeineDrug
Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
CelecoxibDrug
50-200 mg PO. Single dose
PseudoephedrineDrug
15, 30 or 60 mg, PO. Single dose.
MethylphenidateDrug
5 or 10 mg PO. Single dose.
IndomethacinDrug
25, 50 or 75 mg, PO. Singe dose.
IbuprofenDrug
300, 600 or 900 mg, PO. Single dose.
Oxymetazoline 0.05% nasal solutionDrug
1-2 sprays/ nostril. Single dose.
BovrilDietary supplement
6-10 g, PO. Single dose.
AcetazolamideDrug
125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
Rivastigmine tartrateDrug
1.5-6 mg PO. Single dose.
Carbidopa/levodopaDrug
10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
Inflatable abdominal binderDevice
External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
inflatable abdominal binder (sham)Device
External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Increase in seated systolic blood pressure 1-hr post drug compared to baseline.Time frame: 1.5-4 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.